nido-carborane

09/01/1996 - "The specific binding of a nido-carborane to CEA-expressing tumor cells was achieved using this bispecific antibody. "
02/01/2022 - "Water-soluble BODIPY-nido-carborane nanoparticles applied to biocompatibility tumor cell imaging."
12/01/2020 - "The viability of tumor cells following BNCT with 70 μM nido-carborane was reduced to 17.1% compared to irradiated control cells, which did not contain boronated liposomes. "
12/01/2020 - "PEGylated liposome encapsulating nido-carborane showed significant tumor suppression in boron neutron capture therapy (BNCT)."
07/12/2007 - "The less toxic nido-carborane 2 was also tested as a candidate for boron neutron capture therapy, but showed poor tumor retention and low selectivity ratios for boron distribution in tumor tissue versus normal tissue."

01/01/2020 - "This is achieved by taking advantage of the increase in the ligand bite angle when the closo-carborane is reduced to the nido-carborane, resulting in C-C bond rupture and cage opening. "

01/01/2009 - "In vitro toxicity was performed with B16 melanoma cells and showed that the connection of hydrophilic nido-carborane to quinazoline moiety decreases the compound's toxicity. "

11/08/2022 - "Folic acid derivatives containing nido-carborane residues were characterised by high water solubility, low cytotoxicity, and demonstrated a good ability to deliver boron to tumour cells in in vitro experiments (up to 7.0 µg B/106 cells in the case of U87 MG human glioblastoma cells). "

01/25/2002 - "A nido-carborane analogue of tamoxifen, the widely employed breast cancer therapy agent, was prepared as an archetype of a potential new class of antiestrogen and boron neutron capture therapy agent in which the carborane is incorporated within the framework of the parent compound. "